Obesity drug users will regain weight two years after ending medication, review finds
Experts say health authorities need plans to deal with people coming off medicines such as Ozempic and Wegovy
Related reading
Indian weight-loss market becomes ‘bloodbath’ as drugmakers pile in
Consumers await cheaper generics after expiry of patent for Ozempic ingredient
Trump administration slashes Ozempic and Wegovy price for Medicare
US negotiates 71% cost reduction of Novo Nordisk’s obesity drugs for elderly Americans on government health insurance
Weight-loss drugs and Mars bars: Novo Nordisk’s comeback bid
The maker of Wegovy and Ozempic wants to learn lessons from consumer groups to crack the US market
Is Ozempic shaping the workplace?
Offering staff weight-loss drugs can improve productivity and reduce time lost to sickness
Eli Lilly shot helped patients lose 29% of body weight
Trial results are a boost to US pharmaceutical company’s booming obesity business
Novo Nordisk shares plunge after profit warning over US weight-loss copycats
Share slide wipes more than €60bn off value of Danish maker of Ozempic and Wegovy